Clinical trial · no report yet · Phase 3
FOURLIGHT-3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
- NCT06760637 ↗
- Active, not recruiting
- Pfizer
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- PF-07220060; letrozole; abemaciclib; palbociclib; ribociclib
- Arms
- Arm A · Experimental
- Arm B · Active comparator
- Enrollment
- 1,035
- Primary outcomes
- Progression Free Survival (PFS) by BICR
- Sponsor
- Pfizer
- Start
- Jan 6, 2025
- Primary completion
- Jan 2, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06760637 · updated Oct 16, 2026